Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Non-Current Liabilities (2021 - 2023)

Arcturus Therapeutics Holdings (ARCT) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $150.4 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Total Non-Current Liabilities fell 15.16% year-over-year to $150.4 million, compared with a TTM value of $150.4 million through Dec 2023, down 15.16%, and an annual FY2023 reading of $150.4 million, down 15.16% over the prior year.
  • Total Non-Current Liabilities was $150.4 million for Q4 2023 at Arcturus Therapeutics Holdings, down from $176.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $177.3 million in Q4 2022 and bottomed at $128.5 million in Q1 2021.
  • Average Total Non-Current Liabilities over 3 years is $153.0 million, with a median of $144.3 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities dropped 17.09% in 2022, then grew 22.41% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $174.0 million in 2021, then rose by 1.87% to $177.3 million in 2022, then dropped by 15.16% to $150.4 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for ARCT at $150.4 million in Q4 2023, $176.6 million in Q3 2023, and $144.2 million in Q2 2023.